G. Rosen

发表

Photodynamic therapy as a treatment for esophageal squamous cell carcinoma in a dog.

T. Jacobs, G. Rosen, 2000, Journal of the American Animal Hospital Association.

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.

A. Ravaud, L. Dirix, C. Britten, 2018, The Lancet. Oncology.

Anti–Programmed Cell Death 1/Ligand 1 (PD‐1/PD‐L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development

T. Powles, A. Necchi, A. Apolo, 2017, Clinical genitourinary cancer.

Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)

J. Dipersio, I. Aldoss, M. Arellano, 2021, Blood.

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

J. Dipersio, N. Shukla, I. Aldoss, 2022, Blood.

Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.

A. Ravaud, L. Dirix, C. Britten, 2017 .

Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial.

A. Ravaud, L. Dirix, C. Britten, 2017 .

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

S. Armstrong, J. Dipersio, N. Shukla, 2023, Nature.